文献速递静脉血栓栓塞

下腔静脉滤器医疗过失诉讼:做也难,不做也难

Inferior Vena Cava Filter Malpractice Litigation: Damned if You Do, Damned if You Don't.
PubMed 文献 · Ann Vasc Surg · 2018-03-08

该研究分析Westlaw数据库2000年1月1日至2015年12月31日的陪审团裁决,共识别156例涉及下腔静脉滤器(IVCF)的诉讼,其中49例涉及未放置滤器或放置并发症。最常见被告为内科医师(38%)、血管外科医师(19%)和心胸外科医师(12%)。17例(35%)判决原告胜诉,中位赔偿金额为1,092,500美元。涉及肺栓塞(PE)的21例中19例致命(90%),其中8例致命PE案件判决原告胜诉(42%)。结论认为IVCF放置后发生PE并死亡时判决倾向于原告,充分的术前沟通和知情同意可能减少诉讼。

要点

  • 未放置IVCF是最常见的具体索赔(41%),其次为植入失败如错位或植入物对齐不良(24%)。
  • 涉及PE的21例中19例致命(90%),致命PE病例中8例(42%)判决原告胜诉。
  • 17例(35%)判决原告胜诉,中位赔偿金额为1,092,500美元。

核心结论

  • IVCF放置后发生PE并死亡时,判决倾向于原告。
  • 充分的术前计划沟通、IVCF放置决策的透明沟通和知情同意可能减少诉讼频率。
  • 考虑放置IVCF的病情本身伴随显著的医疗过失诉讼风险。

研究设计与样本

  • 研究为对Westlaw数据库2000年1月1日至2015年12月31日陪审团裁决的回顾性分析。
  • 使用检索词「inferior vena cava filter」检索,共识别156例案件,排除重复及滤器仅为附带提及的案件后,纳入49例涉及未放置滤器或放置并发症的案件。

主要发现

  • 最常见被告为内科医师(38%)、血管外科医师(19%)和心胸外科医师(12%)。
  • 最常见索赔为拒绝治疗或延迟治疗(35%的案件)、手术过失(24%的案件)和未诊断及处理并发症(24%的案件)。
  • 最常见具体索赔为未放置IVC滤器(41%)、植入失败如错位和/或植入物对齐不良(24%)、IVC侵蚀/腹膜后出血(6%)和过早停用抗凝(6%)。
  • 17例(35%)判决原告胜诉,中位赔偿金额为1,092,500美元。
  • 涉及PE的21例(43%的案件)中19例致命(90%),致命PE病例中8例(42%)判决原告胜诉;两例非致命PE病例均由被告胜诉。

临床怎么用

  • 作者认为,关于术前计划、IVCF放置决策和知情同意的充分且透明的沟通可能减少诉讼频率。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The aim of this study was to analyze malpractice litigation trends and to better understand the causes and outcomes of suits involving inferior vena cava filters (IVCF) to prevent future litigation and improve physician education. METHODS: Jury verdict reviews from the Westlaw database from January 1, 2000, to December 31, 2015, were reviewed. The search term "inferior vena cava filter" was used to compile data on the demographics of the defendant, plaintiff, allegation, complication, and verdict. RESULTS: A total of 156 cases were identified. Duplicates and cases in which the IVCF was incidentally included were excluded from the analysis. Forty-nine cases involving either failure to place or a complication of IVCF placement were identified. Throughout the last 15 years, there has been increased number of jury verdicts toward IVCF. The most frequent defendants were internal medicine physicians (38%), vascular surgeons (19%), and cardiothoracic surgeons (12%). The most frequent claims were denied treatment or delay in treatment (in 35% of cases), negligent surgery (in 24% of cases), and failure to diagnose and treat complications (in 24% of cases). Of these, the most frequent specific claims were failure to place IVC filter (41%), implantation failure such as misplacement and/or misaligned implant (24%), erosion of IVC/retroperitoneal bleed (6%), and discontinuation of anticoagulation prematurely (6%). Seventeen cases (35%) were found for the plaintiff, with median awards worth of $1,092,500. In the 21 cases where pulmonary embolism (PE) was involved (43% of cases), 19 were fatal (90%). Of the fatal PE cases, 8 cases ended with verdicts in favor of the plaintiff (42%). Both nonfatal PE cases were won by the defense. CONCLUSIONS: IVCF placement with subsequent PE and death results in verdicts that favor the plaintiffs. This study emphasizes that adequate and transparent communication regarding preoperative planning, decision for IVCF placement, and informed consent may reduce the frequency of litigation. Public awareness of complications related to the placement of IVCF is increasing largely and spurned by aggressive advertising and marketing by plaintiff attorneys. Conditions for which IVCF placement is contemplated carry significant risk of malpractice litigation.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Phair J, Denesopolis J, Lipsitz EC, et al. Inferior Vena Cava Filter Malpractice Litigation: Damned if You Do, Damned if You Don't. Ann Vasc Surg. 2018. PMID: 29526534. doi:10.1016/j.avsg.2018.01.093

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。